Bendamustine in the treatment of chronic lymphocytic leukemia

Abstract

Introduction: Although typically an indolent disease, chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world, is incurable. Affected patients frequently require multiple treatment options throughout their lifetime. Bendamustine, a unique alkylating chemotherapeutic, has demonstrated remarkable activity in CLL.

Areas covered: This article reviews the safety and efficacy of bendamustine both as a single agent and in combination with targeted therapies such as rituximab (BR). Given its favorable toxicity profile, BR is the preferred option for elderly patients and those with other comorbidities. Recent data have demonstrated that BR is also reasonable for younger and fit patients. Currently, research efforts are focused on newer biologic therapies, including utilizing new anti-CD20 monoclonal antibodies as well as the addition of immunomodulatory agents and small molecule kinase inhibitors.

Expert opinion: Expanding upon the BR backbone with novel agents chosen based on one's molecular profile is the next step to improving patient outcomes.

Keywords::

• bendamustine
• chronic lymphocytic leukemia
• fludarabine
• rituximab
• small molecule kinase inhibitor